Mark R. Carlson

• Led cross-functional teams to develop strategic solutions for client challenges.
• Advised client on model development (xenograph, syngeneic, and orthotopic).
• Discussed modes of drug delivery.
• Potential cell lines to explore best results.
• Enhanced project delivery timelines by implementing streamlined processes and best practices.

• Conducted xenograft and syngeneic tumor modeling in C57BL/6 NCG and NU/NU backgrounds to assess therapeutic potential of innovative kojin ferroptosis inducers.
• Delivered study compounds via oral, intravenous, and subcutaneous administration to ensure consistent dosing schedules.
• Achieved comprehensive data collection in randomized studies by implanting cells and accurately measuring tumor sizes with digital calipers. Monitored and recorded body weights, food, and water intake to maintain study integrity. Executed takedowns at study termination, successfully collecting blood samples through submandibular and heart stick methods, and gathered organ samples for in-depth biomarker studies.
• Conducted regular health assessments of mice to identify and report behavioral or health issues.
• Provided insights and expertise during weekly pharmacology meetings.
• Facilitated relocation of supplies and established vivarium site at new facility.
• Fulfilled comprehensive protocol requirements for new vivarium to ensure compliance and operational readiness.

• Conducted comprehensive syngeneic oncology studies in both balb/c and c57bl/6 models to assess therapeutic potential of innovative Evelo microbes.
• Assisted in conducting randomized studies on implanted cells and dosed study microbes via oral administration. Measured tumor volume using digital calipers and performed takedowns at study completion. Collected serum, tumors, and lymph nodes for ex vivo analysis and contributed to data presentation at team meetings.
• Managed procurement of all mouse strains for oncology research group.
• Oversaw sensitization dosing for ear challenges and serum and tissue analysis in Evelo in-house KLH/DTH model using C57BL/6 mice.
• Led development of an apo-induced asthma model to enhance inflammation research capabilities.
• Conducted imaging on murine small intestines to ascertain precise positioning of study-related fluorescent mini tablets.

• Performed all aspects of in vivo tumor model studies.
• Developed in-house models for CT26, MC38, B16/F10, 4T1, A20, EG7 cell lines.
• Responsible for cell line maintenance, (passaging cell lines and expanding cell lines for implantation.
• Tabulated, graphed and presented data at group meetings, team meetings and yearly off-site meetings.
• Developed protocol for mini tablet dosing in both the BALB/c and C57BL/6 mouse backgrounds.
• Performed validation in vivo studies when the company changed vivarium sites.
• Assisted in tissue collection for Oncology, Inflammation and Metabolism teams.

Served as a consultant to finalize critical in vivo studies following company closure announcement.

Conducted all phases of in vivo oncology research aimed at evaluating tumor responses to cutting-edge antibody-drug conjugates.

Facilitated implantation of cells and dosing of compounds in randomized cohorts, measuring tumor development and gathering blood and organ samples for further processing.

• Oversaw all facets of in vivo efficacy experiments in athymic nude mice to evaluate effectiveness of novel antibody conjugates on tumor activity.
• Conducted all aspects of tissue culture to support research initiatives, encompassing cell maintenance, passaging, line expansion, and freeze runs for a variety of xenograft models.
• Executed subcutaneous implantation of cells and administered dosing for study conjugates, ensuring accurate tumor measurement using electronic calipers.
• Conducted comprehensive pharmacokinetic analyses to evaluate antibody conjugate levels in plasma samples.
• Surgically removed and fixed tumors for immunohistochemistry analysis.
• Led development of syngeneic models utilizing Balb/c, FVB, and C57BL/6 mouse strains.
• Executed immunogenicity studies utilizing Balb/c and C57BL/6 mouse models.
• Facilitated blood analysis for pharmacology group utilizing Vetscan instrument.
• Executed implementation and start-up of new offsite in vivo lab.

• Collaborated within research project team to advance strategic R&D objectives.
• Delivered in vivo data presentations to enhance project discussions at global bi-monthly project team meetings and monthly group meetings.
• Facilitated information exchange regarding project details among functional groups.
• Informed in vivo group members of critical decisions made during team meetings.
• Led development of in vivo POC model in rats for endocrinology research.
• Delivered in vivo project data presentations at two Global Project Review offsite corporate meetings in France.
• Developed net models in athymic nude mice to advance research focus.
• Facilitated serum separation and performed ELISA testing to detect testosterone levels in rat blood samples.
• Led comprehensive evaluations of oncology compounds through multiple exploratory studies to enhance research collaboration.
• Facilitated toxicological studies on newly synthesized compounds to assess bioavailability over time.